11 High Growth Micro-cap Stocks to Buy

Page 6 of 10

5. Outset Medical, Inc. (NASDAQ:OM)

Number of Hedge Fund Holders: 23

Market Capitalization: $88.85 million

5-year Revenue Growth: 49.79%

On January 7, Stifel analyst Rick Wise lowered the price target on Outset Medical, Inc. (NASDAQ:OM) to $8 from $14 while maintaining a Buy rating on the shares. The adjustment reflects near-term pressures in MedTech following 2025, though the firm remains constructive on the sector overall for 2026.

Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In Q3 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Tablo console sales increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.

Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of healthcare’s largest and most expensive segments, through innovative technology, research, and North American manufacturing operations.

Page 6 of 10